Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

References

• Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26, 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomcis Outcomes Res.8(4), 357–371 (2008).
   PubMedGoogle Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res.9(5), 475–484 (2009).
   PubMedGoogle Scholar
• Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy8, 7–24 (2010).
   PubMedGoogle Scholar
• McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res.10(1), 73–85 (2010).
   PubMed Web of Science ®Google Scholar
• Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res.9(6), 569–581 (2009).
   PubMedGoogle Scholar
• Hakonsen H, Horn A, Toverud EL. Price control as a strategy for pharmaceutical cost-containment – what has been achieved in Norway in the period 1994–2004? Health Policy90, 277–285 (2009).
   PubMed Web of Science ®Google Scholar
• Fattore G, Jommi C. The last decade of Italian pharmaceutical policy – instability or consolidation? Pharmacoeconomics26, 5–15 (2008).
   PubMed Web of Science ®Google Scholar
• Simoens S. Trends in generic prescribing and dispensing in Europe. Expert. Rev. Clin. Pharmacol.1(4), 497–503 (2008).
   PubMedGoogle Scholar
• Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin.23, 2647–2654 (2007).
   PubMed Web of Science ®Google Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics27, 435–438 (2009).
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals3, 2470–2494 (2010).
   Google Scholar
• McKee M, Stickler D, Martin-Moreno J. Protecting health in hard times – Europe’s health ministers exchange experiences on the impact of the economic crisis. BMJ341, 681–682 (2010).
   Google Scholar
• Aaserud M, Austvoll-Dahlgren A, Kösters JP et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst. Rev.19(2), CD005979 (2006).
   Google Scholar
• Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26, 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoeconomcis Outcomes Res.9(1), 65–83 (2009).
   PubMedGoogle Scholar
• Sakshaug S, Furu K, Karlstad O et al. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. Br. J. Clin. Pharmacol.64, 476–481 (2007).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy94, 221–229 (2010).
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M et al. Comparing policies to enhance the utilisation generics across Europe: changes seen and global implications. Expert Rev. Pharmacoeconomics Outcomes Res.10(6), 707–722 (2010).
   PubMed Web of Science ®Google Scholar
• Martikainen J, Saastamoinen L, Korhonen M et al. Impact of restricted reimbursement on the use of statins in Finland – a register-based study. Med. Care48, 761–766 (2010).
   PubMed Web of Science ®Google Scholar
• Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. Health Policy85, 305–313 (2008).
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems – a position paper. Eur. J. Clin. Pharmacol.64, 1137–1138 (2008).
   PubMed Web of Science ®Google Scholar
• Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med.359, 333–335 (2008).
   PubMed Web of Science ®Google Scholar
• Kjoenniksen I, Lindbaek M, Grannas A. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm. World Sci.28, 284–289 (2006).
   PubMed Web of Science ®Google Scholar
• Hakonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr. Med. Res. Opin.25, 2515–2521 (2009).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7, 1–11 (2009).
   PubMedGoogle Scholar
• Fretheim A, Håvelsrud K, MacLennan G et al. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis. PLoS Med.4(7)e232, 1178–1186 (2007).
   Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J.28, 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• Josan K, Majumdar S, McAlister F. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ178, 576–584 (2008).
   PubMed Web of Science ®Google Scholar
• Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA296, 2947–2953 (2006).
   PubMed Web of Science ®Google Scholar
• Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch. Intern. Med.167, 950–955 (2007).
   PubMed Web of Science ®Google Scholar
• Leonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol.102, 2047–2056 (2007).
   PubMed Web of Science ®Google Scholar
• Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ336, 2–3 (2008).
   PubMed Web of Science ®Google Scholar
• Katz MH. Failing the acid test – benefits of proton pump inhibitors may not justify the risks for many users. Arch. Intern. Med.170, 747–748 (2010).
   PubMed Web of Science ®Google Scholar
• Howell M, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med.170, 784–790 (2010).
   PubMed Web of Science ®Google Scholar
• Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? Eur. J. Clin. Pharmacol.56, 723–727 (2000).
   PubMed Web of Science ®Google Scholar
• Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers’ and physicians’ opinions of experiences with generic substitution during the first year in Finland. Health Policy82, 366–374 (2007).
   PubMed Web of Science ®Google Scholar
• Andersson K, Jorgensem T, Carlsten A. Physicians’ opinions and experiences of the pharmaceutical benefits reform. Scand. J. Public Health34, 654–659 (2006).
   PubMed Web of Science ®Google Scholar
• Anon. Good professional practice. ISDB Newsletter20, 5–11 (2006).
   Google Scholar
• Gilley J. Towards rational prescribing. BMJ308, 731–732 (1994).
   PubMed Web of Science ®Google Scholar
• Walley T, Folin-Galo P, Stephens P, Van Ganse E. Trends in prescribing and utilisation of statins and other lipid lowering drugs across Europe 1997–2003. Br. J. Clin. Pharmacol.60, 543–551 (2005).
   PubMed Web of Science ®Google Scholar
• Godman B, Buscics A, Burkhardt T et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria; impact and implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res.10(2), 199–207 (2010).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care17, 179–189 (2009).
   PubMedGoogle Scholar
• Bero L, Grilli R, Grimshaw J et al. Getting research into practice. BMJ317, 465–468 (1998).
   PubMed Web of Science ®Google Scholar
• Fein O. Keep the single payer vision. Medical Care48, 759–760 (2010).
   PubMed Web of Science ®Google Scholar
• Norman C, Zarrinkoub R, Hasselström J et al. Potential savings without compromising the quality of care. Int. J. Clin. Pract.63, 1320–1326 (2009).
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract.62, 480–484 (2008).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract.62, 76–87 (2008).
   PubMed Web of Science ®Google Scholar